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Abstract
Background: Bayesian hierarchical models have been proposed to combine evidence from different types of study designs.
However, when combining evidence from randomised and non-randomised controlled studies, imbalances in patient
characteristics between study arms may bias the results. The objective of this study was to assess the performance of a
proposed Bayesian approach to adjust for imbalances in patient level covariates when combining evidence from both types
of study designs.
Methodology/Principal Findings: Simulation techniques, in which the truth is known, were used to generate sets of data
for randomised and non-randomised studies. Covariate imbalances between study arms were introduced in the non-
randomised studies. The performance of the Bayesian hierarchical model adjusted for imbalances was assessed in terms of
bias. The data were also modelled using three other Bayesian approaches for synthesising evidence from randomised and
non-randomised studies. The simulations considered six scenarios aimed at assessing the sensitivity of the results to
changes in the impact of the imbalances and the relative number and size of studies of each type. For all six scenarios
considered, the Bayesian hierarchical model adjusted for differences within studies gave results that were unbiased and
closest to the true value compared to the other models.
Conclusions/Significance: Where informed health care decision making requires the synthesis of evidence from
randomised and non-randomised study designs, the proposed hierarchical Bayesian method adjusted for differences in
patient characteristics between study arms may facilitate the optimal use of all available evidence leading to unbiased
results compared to unadjusted analyses.
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Introduction
Evidence of the effects of interventions is a critical component of
health care decision making as it contributes to the comparison of
alternative interventions in terms of their relative costs and effects.
Such comparisons form the basis of decisions regarding the
economically efficient allocation of scarce resources. An all
available evidence approach to informing these decisions may
require the synthesis of evidence from different types of study
designs (e.g., randomised controlled trials (RCTs) and comparative
non-randomised or observational studies). Recently, Bayesian
hierarchical models have been proposed to combine evidence
from different types of study designs such as randomised and non-
randomised studies [1,2].
Due to their inherent design, RCTs are more likely to be
balanced in terms of patient characteristics between study arms
than non-randomised studies, but they are subject to strict
inclusion and exclusion criteria which may limit their generalisa-
bility. Despite the greater generalisability associated with non-
randomised or observational studies, the increased likelihood of
imbalances among the study arms compared to RCTs suggests the
results may be more subject to the potential confounding effects of
extraneous variables. Although other sources of bias, both internal
(e.g., performance, attrition) and external (e.g., population,
intervention) [3], may exist, it is the increased likelihood of
imbalances among the non-randomised studies that constitutes the
principal difference between randomised and non-randomised
studies [4]. When these imbalances exist in factors that are also
related to the outcome, bias may be introduced.
In order to address the problem of bias due to imbalances
between study arms in non-randomised studies, we proposed [5]
an extension to the Bayesian three-level hierarchical model,
initially developed by Prevost et al. [1], and applied it to a case
study. The proposed approach involved adjusting study estimates
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between study arms. Results from the case study indicated a shift
in the estimates for the model adjusted for differences towards the
estimate for the randomised studies alone [5]. While this shift lends
credence to the proposed model’s ability to adjust for imbalances,
these results pertain only to a single applied example.
Given the importance of using all available evidence for decision
making and the increased use of Bayesian hierarchical models to
combine evidence from different study types [6,7], the objective of
this paper was to assess the performance of the proposed Bayesian
approach to synthesise evidence from randomised and non-
randomised studies and adjust for imbalances in patient
characteristics within studies. To meet the study objective, we
conducted a simulation study to generate sets of randomised and
non-randomised studies in which bias that could be explained by
covariate imbalances was introduced in the non-randomised
studies. The data were also modelled using three other Bayesian
approaches: 1) results unadjusted for potential imbalances [1], 2)
results adjusted for aggregate study values (e.g., mean age) [1] and
3) downweighting the potentially biased non-randomised studies
[2]. The sensitivity of the results to changes in the impact of the
imbalances and the relative number and size of studies of each
type was also assessed.
Methods
The following presents the four models being compared, the
scenarios considered, and the methods used to conduct the
simulation study.
2.1 Bayesian methods to combine evidence from
randomised and non-randomised studies
2.1.1 Unadjusted for potential imbalances (model I). The
first model presented is the Bayesian three-level hierarchical model
unadjusted for potential imbalances. We undertook this analysis
using a binomial model in which the odds of the event were
calculated for each study and study arm level information was
incorporated into the model. We assumed that for each study type
(indexed by i) there were ki studies (indexed by j), which allows for a
different number of studies for each study type (i.e., randomised and
non-randomised).
The model can be written as follows:
rCij*Binomial pCij,n Cij
  
and rTij*Binomial pTij,n Tij
  
ð1Þ
log odds pCij
  
~cij and log odds pTij
  
~cijzyij ð2Þ
yij*Normal(hi,si
2) ð3Þ
hi*Normal(m,t2) ð4Þ
(i=1 or 2 for the 2 study types; j=1,…,ki studies).
At the first level of the model, represented by equations one and
two, it was assumed that the number of events in each arm in the
jth study of type i (i.e., rCij and rTij for control (C) and treatment
(T), respectively) followed a binomial distribution defined by the
proportion of patients who experienced the event in each arm in
the jth study of type i (i.e., pCij and pTij) and the total number of
patients in each arm in the jth study of type i (i.e., nCij and nTij).
Equation two described the log odds for the event in the control
(cij) and treatment (cij+yij) arms of each of the ki studies.
The second level of the model, represented by equation three,
assumed that the log odds ratio comparing treatment and control,
yij, followed a normal distribution with a mean of hi (i.e., the
overall intervention effect in the ith type of studies). The within-
study-type variability for studies of type i was represented by si
2.
At the third level of the model, represented by equation four, the
study-type effects were distributed about an overall population
effect, m, with t
2 representing the between-study-type variability.
Prior distributions for the unknown model parameters were
intended to be vague. Normal priors with mean zero and variance
0.26 truncated to be positive, were specified for the random-effects
standard deviations (si,t). These priors support equality between
studies while discounting substantial heterogeneity and represent
what may be considered reasonable priors in many situations [8].
In keeping with Prevost et al. [1], Normal priors with mean zero
and variance ten were used for the overall population effect (m).
Vague Normal priors with mean zero and variance 1000 were
assigned to the log odds (cij’s).
2.1.2 Adjustment using study arm differences (model
II). The following presents the extension of the Bayesian three-
level hierarchical model (I) proposed by McCarron et al. [5]. The
model was specified as before except equation three was replaced
by equation five.
yij*Normal(hiz
X M
m~1
am xmTij-xmCij
  
, si
2) ð5Þ
(i=1 or 2 for the 2 study types; j=1,…,ki studies; m=1,..,M
confounders).
As shown in equation five, this model assumed that the log odds
ratio, yij, followed a normal distribution with a mean which was
the sum of hi (i.e., the overall intervention effect in the ith type of
studies) and a study specific bias adjustment,
P M
m~1
am xmTij-xmCij
  
,
that was proportional to the relative differences between the study
arms in each of the studies. In this expression, xmTij and xmCij were
the values of the m-th potential confounder in each of the study
arms (i.e., treatment and control) in the jth study of type i while am
represented the coefficient for the m-th potential confounding
variable across all the studies. This variable described the impact
of the imbalances on the study specific log odds ratios.
The priors for the unknown parameters were the same as for
model I with the addition of a vague Normal prior with mean zero
and variance 1000 for the coefficient (am) for the m-th potential
confounder.
2.1.3 Adjustment using aggregate study values (model
III). This approach was initially proposed by Prevost et al. [1] to
try to explain between study heterogeneity. The model was
specified in the same way as in section 2.1.1, except equation three
was replaced by equation six:
yij*Normal(hiz(am|xmij), si
2) ð6Þ
(i=1 or 2 for the 2 study types; j=1,…,ki studies; m=1,..,M
confounders).
In this approach, xmij represented the value of the m-th
potential confounder aggregated across study arms (i.e., treatment
and control) in the jth study of type i. This is in contrast to the
previous approach which adjusted using the difference in the m-th
potential confounder between the study arms. The prior
distributions were the same as in the previous models.
Bayesian Hierarchical Models and Adjustment
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IV). The informative prior approach used by Sutton and
Abrams [2] included the evidence from the non-randomised
studies via the prior for the treatment effect and combined this
with a likelihood based only on the data from the randomised
studies.
As in Sutton and Abrams [2], we centred the informative prior
for the population mean (m) on the non-randomised pooled
estimate but used a variance four times larger than that of the
RCTs. Such a prior reflects scepticism regarding the non-
randomised evidence and would be appropriate in situations
where a researcher believes that although the non-randomised
evidence provides some information, concern that serious biases
may exist (e.g., as a result of imbalances in study arms) means that
it should be treated with caution. The pooled estimate for the non-
randomised studies was generated using a two-level Bayesian
hierarchical model (simple Bayesian random-effects model). We
chose to use a variance that was four times as large as that for the
RCTs, because this was the variance inflation factor used by
Sutton and Abrams [2]. Other choices are possible, however. The
more the variance from the non-randomised studies is inflated, the
more their evidence is downweighted.
2.2 Assessment framework
The effect of these models is to produce a weighted average of
the evidence from the randomised and non-randomised studies,
where the weights are determined either implicitly, as in the
Bayesian three-level hierarchical models (I,II and III), or explicitly,
as in the informative prior approach (model IV) [9]. The results for
each of the four models were simulated under different scenarios
which varied as a function of the impact of the imbalances in the
non-randomised studies, and the relative number and size of
studies of each type. These factors were selected as they were
deemed to be the most important in terms of calculating a
weighted average of the evidence from the randomised and non-
randomised studies. For the purpose of this simulation study,
imbalance in a single continuous covariate (i.e., age) was
considered, but the analysis could be extended to adjust for other
covariates [5]. Imbalances in age between study arms were only
assumed for the non-randomised studies, in keeping with the
general assumption that due to their design RCTs are more likely
to be balanced.
Table 1 presents the parameters used in the six scenarios
considered. Two different values were investigated for the impact
of the imbalances in the non-randomised studies (am). Log scale
values of 0.10 and 0.50 were chosen as they represent lower and
upper estimates of what may appear reasonable in terms of
variation in the between-study log odds ratios [8]. A magnitude of
0.10 would indicate that there is not much systematic variation in
the study specific log odds ratios while a magnitude of 0.50 would
result in much more systematic variation. This means that, all else
being equal, every one unit increase in the difference in age
between study arms would result in an increase in the study
specific log odds ratio of 0.10 or 0.50. For example, the impact of
going from no imbalances to a one year difference in mean age
between study arms would increase the study specific log odds
ratio from a true value of 20.20 to values of 20.10 and 0.30
respectively.
The impact of the precision and quantity of information
contained in each of the two types of studies (i.e., randomised and
non-randomised) was examined by comparing study sizes of 100 to
500 patients per arm and 500 to 1000 patients per arm for the
randomised and non-randomised studies respectively and four
randomised studies with 40 non-randomised studies. These values
reflect the fact that non-randomised studies tend to be larger than
randomised studies [2]. Also, the number of studies in a meta-
analysis of RCTs in medicine tends to be small and it is common
to see meta-analysis performed on five or fewer studies [10]. These
values were also based on the systematic literature review
comparing endovascular aneurysm repair (EVAR) and open
surgical repair (OSR) [11] that informed the results of the previous
case study [5]. For the six scenarios presented in Table 1, it was
assumed that the true log odds ratio was 20.20, which
corresponds roughly to an odds ratio of 0.82. Although this
represented a much more modest treatment effect than was
observed for 30-day mortality in either the randomised or non-
randomised studies in the EVAR case study [5], this odds ratio
may better reflect the magnitude of relative treatment effects seen
in practice for other conditions.
2.3 Simulation study
As the truth is known, simulation studies allow one to assess
model performance relative to this known truth [12]. This is in
contrast to a case study, like the one in which we initially proposed
model II, where the truth is not known. In order to demonstrate
empirically whether model II is able to adjust for imbalances we
have conducted a simulation study. The simulation study was
concerned with synthesising evidence from randomised and non-
randomised studies and adjusting for bias due to imbalances in the
non-randomised studies, consequently we have simulated data
under a model that produces imbalances in the non-randomised
studies (see Figure S1).
Each simulated data set consisted of a number of hypothetical
randomised (i.e., four) and non-randomised studies (i.e., four or 40)
comparing treatment and control groups. The outcome was
defined as a dichotomous variable indicating the occurrence or not
of the event of interest (i.e., death). Each data set for each of the
two study types was generated by the following model:
rCij*Binomial pCij,n Cij
  
and rTij*Binomial pTij,n Tij
  
ð7Þ
log odds pCij
  
~cij and log odds pTij
  
~cijzyij ð8Þ
yij~hizaage xageTij{xageCij
  
ð9Þ
The number of subjects in the control (nCij) and treatment (nTij)
groups in the jth study of type i were assumed to be equal and were
sampled from a uniform distribution of either 100 to 500 or 500 to
1000 patients. Based on the data for perioperative mortality from
the previous systematic literature review [11] the probability for
the event (i.e., death) in the control group (pCij) in each of the ki
studies was drawn from a beta distribution with mean 0.04 and
variance 0.001. For scenarios 1–6, the true log-odds ratio (hi) was
20.20 for both the randomised and non-randomised studies. A
possible explanation for the effect of treatment on mortality in our
simulation study was assumed to be differences in age between
study arms (xageTij2xageCij), as shown in equation nine. Age is
related to mortality and aage addresses the relationship between
differences in age and mortality. The variables xageTij and xageCij
are both sampled from uniform distributions based on the age
distribution observed in the previous systematic literature review
(i.e., xageTij,uniform(75,90), xageCij,uniform(70,85)) [11]. As
randomisation will likely minimize differences between study
groups, xageTij and xageCij were assumed to be equal in the
Bayesian Hierarchical Models and Adjustment
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number of events and subjects as well as for the age in the control
and treatment groups given the impact of the imbalances (aage),
the number of randomised and non-randomised studies, and the
study size being considered.
In order to justify the number of simulations (i.e., 100), we
calculated the difference in mean treatment effects for each of the
models (I,III,IV) relative to the difference model (II) and compared
these to the standard errors of the differences in treatment effects.
This was repeated across 100 simulations for each of two seeds
(starting values for the simulation). The results across both seeds
suggested that 100 simulations were sufficient to average out the
sampling variation. For scenario 1, for example, the differences in
mean treatment effects relative to model II were 0.27 for model I,
0.28 for model III and 0.10 for model IV. The standard errors of
the differences were 0.02, 0.03 and 0.02 respectively for the three
comparisons. For the second seed the mean differences were 0.27,
0.28, and 0.09 respectively and the standard errors were
approximately 0.02 across all three comparisons, illustrating that
sampling variation was small compared to the size of the
differences that were detected.
Markov chain Monte Carlo (MCMC) simulation using the
Gibbs sampling technique was used to assess the models. The
Brooks, Gelman & Rubin, Geweke and Heidelberger and Welch
diagnostics available in the package Bayesian Output Analysis
[13], performed on two chains, were used to assess convergence.
To provide a sense of the convergence diagnostics we give the
Brooks, Gelman & Rubin diagnostics for the overall log odds ratio
(m) for each of the models in scenario 4: the estimated values for
the ratio of total variability to within-chain variability were
approximately 1.01, 1, 1.01, and 1for models I through IV
respectively, suggesting little between-chain variability. Based on
these and the results from the other diagnostics, we decided to use
a burn-in of 50 000 iterations for every model for each simulated
data set except for the unadjusted and aggregate models in
scenarios 2 and 5, which required a longer burn-in of 100 000
iterations to converge. After discarding the burn-in iterations, we
sampled from a further 10 000 iterations with a thin rate of 20, for
each of the two chains, such that summary statistics for the
parameter values were based on thinned samples of 1000
iterations.
The simulated data sets were generated in R 2.9.2 [14]. The
Bayesian hierarchical models (I,II,III,IV) were fitted to each
generated data set in WinBUGS 1.4 [15] using the R 2.9.2
package R2WinBUGS. To validate the simulation model the
mean value for aage was calculated across all 100 simulations for
model II and compared to the true value. The results for the six
scenarios were 0.10, 0.10, 0.10, 0.52, 0.51, and 0.51 respectively.
These correspond to true values of 0.10 for scenarios 1–3 and 0.50
for scenarios 4–6.
2.4 Criteria for assessing model performance
The median value of the overall log odds ratio (m) was calculated
for each simulated data set. The four different models for the six
scenarios were then evaluated relative to the true value using the
criterion of bias under repeated sampling. The estimated bias in
the log odds ratio was defined as the mean value of the median log
odds ratios across the simulated samples minus the true value [12].
As the results may be subject to sampling variation, we also
reported the bias divided by its standard error, which is equal to
the standard error of the mean of the median log odds ratios and
would be expected to follow a standard normal distribution. If an
estimation technique is unbiased, we would expect the observed
bias divided by its standard error (Z-statistic) to lie between 21.96
and +1.96 ninety-five percent of the time. Formulas for the various
calculations are given in Figure S1.
Results
Table 2 shows the point estimates for the mean of the median
log odds ratios, and the associated standard errors of the mean
median log odds ratios as well as the estimated bias and Z-statistics
for each of the four models in the six scenarios. As shown in this
table, the estimates of the pooled effect size appear to be unbiased
for the model adjusted for differences (model II) across all six
scenarios. The informative prior approach appears to give less
biased results than the model adjusted for aggregate study values
while bias is roughly equal for both the model adjusted for
aggregate values and the unadjusted model. An increase in the
study arm size for the non-randomised studies relative to the
randomised studies tends to increase the precision of the estimates
for all of the models. However, combining evidence from four
randomised studies and 40 non-randomised studies seems to
increase the precision of the estimates the most compared to the
other scenarios. In general, as might be expected, there is more
variability in the model estimates when the assumed value of the
impact of imbalances in age across all of the studies (aage)i s
greater. The most extreme cases of bias appear to occur with the
aggregate and unadjusted models in scenario five, when the value
of aage is 0.50 and there are four randomised and 40 non-
Table 1. Simulation parameters for scenarios 1–6.
Criteria
Scenario
Impact of imbalances
in non-randomised
studies
a
Number of
randomised studies
Number of non-
randomised studies
Study arm size
randomised studies
b
Study arm size non-
randomised studies
b
True overall log
odds ratio
1 0.10 4 4 100–500 100–500 20.20
2 0.10 4 40 100–500 100–500 20.20
3 0.10 4 4 100–500 500–1000 20.20
4 0.50 4 4 100–500 100–500 20.20
5 0.50 4 40 100–500 100–500 20.20
6 0.50 4 4 100–500 500–1000 20.20
aaage measured on the log scale,
bsampled from a uniform distribution.
doi:10.1371/journal.pone.0025635.t001
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are 40 non-randomised studies. However, as shown in table 2, the
extent of the bias is more pronounced in scenario five compared to
scenario two, where the magnitude of the impact of the imbalances
is relatively smaller.
Figure 1 presents the point estimates and the confidence
intervals for the overall log odds ratio (m) for each of the models in
the six scenarios. Comparing the point estimates to a log odds ratio
of zero (i.e., no effect) indicates that among the aggregate and
unadjusted models and even the informative prior, for scenarios 4–
6, the impact of the imbalances is such that it alters the estimate as
to whether or not the treatment is effective, thus deviating from the
truth.
Discussion
This simulation study demonstrated that when bias in the non-
randomised studies can be explained by covariate imbalances
between study arms, the proposed Bayesian three-level hierarchi-
cal model adjusted for differences in patient characteristics within
studies can handle this problem. Using simulation techniques,
wherein the truth is known, we have been able to produce
empirical evidence that this is the case. Failure to take into account
these imbalances could bias the results.
Specifically, six scenarios incorporating different aspects of the
impact of the imbalances and the relative numbers and sizes of
each study type were considered. The results from the model
adjusted for differences in patient characteristics within studies
were, in every scenario, unbiased and closest to the true value
compared to the results from the other models. This trend was
robust to changes in the magnitude of the impact of the
imbalances across studies as well as to both the relative number
and size of studies being combined. Results also showed that none
of the previously proposed Bayesian approaches could handle the
issue of bias due to covariate imbalances. In certain instances, the
bias observed among the other models was such that it changed
the treatment estimate from one of benefit to one of harm. This
could have implications in terms of health care decision making.
A practical limitation of the study concerns the number of
simulations. There are no exact standards for the number of
simulations necessary to average out sampling variation. We had
initially considered performing 1000 simulations, but given the
breadth of the study in terms of the number of scenarios
considered and the associated run times, which ranged from five
to 40 hours (1.83 GHz processor) for the 100 simulations,
depending on the scenario, we determined that this would not
be feasible. All of the parameters in each of the models were
sampled and none were marginalised. This was done to ensure
that the appropriate probabilistic dependence between the
unknown parameters was propagated through the model. This
could be particularly important when propagating inferences
which are likely to be strongly correlated. For example, the current
study considers both baseline levels and treatment differences
estimated from the same studies [8]. In addition, the study is based
on the assumption that there is also some association with
Table 2. Simulation results comparing Bayesian hierarchical models for scenarios 1–6.
Scenario Model
Mean median
log odds ratio
Standard error mean
median log odds ratio Bias Z-statistic
1 Unadjusted (I) 0.06253 0.02268 0.26253 11.57665
Adjusted for differences (II) 20.20836 0.02374 20.00836 20.35207
Adjusted for aggregate values (III) 0.07407 0.02622 0.27407 10.45383
Informative prior (IV) 20.11156 0.02437 0.08844 3.62828
2 Unadjusted (I) 0.18750 0.01330 0.38750 29.12960
Adjusted for differences (II) 20.20216 0.01010 20.00216 20.21398
Adjusted for aggregate values (III) 0.19520 0.01355 0.39520 29.17138
Informative prior (IV) 20.12240 0.02385 0.07760 3.25356
3 Unadjusted (I) 0.05473 0.02079 0.25473 12.25142
Adjusted for differences (II) 20.23125 0.01816 20.03125 21.72104
Adjusted for aggregate values (III) 0.05979 0.02189 0.25979 11.86562
Informative prior (IV) 20.13908 0.02235 0.06092 2.72561
4 Unadjusted (I) 0.87357 0.06602 1.07357 16.26034
Adjusted for differences (II) 20.22000 0.02535 20.02000 20.78904
Adjusted for aggregate values (III) 0.98388 0.07572 1.18388 15.63405
Informative prior (IV) 0.85343 0.09327 1.05343 11.29504
5 Unadjusted (I) 1.14790 0.03313 1.34790 40.67943
Adjusted for differences (II) 20.20083 0.01146 20.00083 20.07268
Adjusted for aggregate values (III) 1.28827 0.03734 1.48827 39.85580
Informative prior (IV) 0.64133 0.05340 0.84133 15.75488
6 Unadjusted (I) 0.70170 0.06319 0.90170 14.27030
Adjusted for differences (II) 20.19981 0.01721 0.00019 0.01117
Adjusted for aggregate values (III) 0.78753 0.06303 0.98753 15.66646
Informative prior (IV) 0.69489 0.09509 0.89489 9.41122
doi:10.1371/journal.pone.0025635.t002
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sample all parameters in our simulation study. In other cases,
perhaps, some parameters could be marginalised which could
potentially improve the speed of the algorithm. Concerns
regarding the number of simulations conducted were mitigated
by comparing the effect sizes relative to the standard errors for
each of two data sets. The results of these comparisons suggested
we could be reasonably confident that the number of simulations
was adequate.
Another potential limitation is that we assumed that the only
source of variation between study estimates was due to imbalances
between treatment arms in a single patient characteristic. As such,
the underlying study type effects in both the randomised and non-
randomised studies were assumed to be the same, which may not
always be true. In practice, there may be other unexplained
reasons why the estimates may differ. For example, patients
enrolled in RCTs may be comparatively younger than those
enrolled in non-randomised studies. The result of incorporating
different values for the study type treatment effects is that there is
no longer one true underlying effect, as there was in the six
scenarios we considered. As the objective of the simulation study
was to evaluate the performance of the proposed model in terms of
adjusting for bias due to covariate imbalances, we did not address
this issue in our study. Such an analysis would likely require a
Figure 1. Overall log odds ratios for Bayesian hierarchical models scenarios 1–6. The overall log odds ratios (m) and associated 95%
confidence intervals (CIs) from the simulations are presented for scenarios 1–6. A solid line intersects the x axis at the true overall log odds ratio (i.e.,
20.20). A dashed line intersects the x axis at no effect (i.e., 0).
doi:10.1371/journal.pone.0025635.g001
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involve its own base case assuming no imbalances. This would
allow one to distinguish between the borrowing of strength across
study types that is part of Bayesian hierarchical modelling and the
appropriate adjustment for imbalances. This is left for future
research. Future research could also assess the practical implica-
tions of these results within a decision analytic model. Another
potential area of research could be the choice of prior distribution
for the random-effects standard deviations (si,t). In contrast to the
half-normal priors used in the current analysis, other suggestions
include an inverse gamma distribution such as 1/si
2,
Gamma[0.001,0.001]. Though, because such a distribution gives
a high weight near zero for the standard deviation, the true
variability may be underestimated [8,10]. As the current analysis
relies on the existence of within-study-type and between-study-
type variability, such a prior could be problematic, especially in
those scenarios with only four non-randomised studies.
Despite potential limitations, we believe the results of this
simulation study demonstrate the ability of the Bayesian three-level
hierarchical model adjusted for differences to account for
imbalances in patient characteristics within non-randomised studies
that could bias the results. Such an approach does, however, rely on
authors reporting the main characteristics of their study popula-
tions. This is important as the unadjusted model performed poorly
in the presence of imbalances between study arms, as shown in our
simulations. Unfortunately, few studies report all relevant covariates
[4]. For example, in the initial case study, over half of the non-
randomised studies were missing information on at least one
covariate. Based on the results of our study, and the performance of
the proposed approach, authors should be encouraged to improve
the reporting of covariate information as this would facilitate
adjustment for future evidence synthesis. The performance of the
informative prior approach depends onhowwell oneanticipates the
impact of the imbalances on the results and downweights the
evidence accordingly. Though the factor we used to inflate the
variance and downweight the non-randomised studies was based on
Sutton and Abrams [2], this value was somewhat arbitrary. In
practice the selection of an appropriate discount factor would
require a careful consideration of the relative weight and
information each study type should contribute to the analysis.
Nonetheless, the factor of four used for model IV in the current
study means that in calculating a weighted average of both study
types, the randomised studies would contribute the majority of the
information. This reflects the existence of scepticism regarding the
evidence generated by the non-randomised studies, but assumes
there is still some value in combining these studies with the
randomised studies. As has been demonstrated, by holding constant
the amount by which the non-randomised studies were down-
weighted, downweighting is not an automatic procedure, nor does it
explicitly address the potential for imbalances in patient character-
istics within individual studies. Only one of the methods for
downweighting used in the case study was considered in this
analysis. The number of failures that occurred when simulating
values for the prior constraint method [1] suggested that it could not
be used reliably in the situations being investigated. However, the
results of the case study suggest it is unlikely that this method would
be able to handle the covariate imbalances, especially in those
scenarios where the relative number or size of the non-randomised
studies was greater compared to the randomised studies. Adjust-
ment using aggregate study values attempts to explain heterogeneity
acrossstudies byadjustingfor variationinstudy level characteristics.
However, the absence of variation in mean age across studies does
not preclude the presence of imbalances in age within studies. This
will not be adjusted for using aggregate study values.
Based on the six scenarios considered, covariate adjustment using
differences in patient characteristics between study arms (i.e., model
II) provides a way of adjusting for imbalances that is robust to
changes in the magnitude of the impact of the imbalances and the
relative number and sizeof the studies of each type (i.e., randomised
or non-randomised studies). This is important as this new
methodology provides a way to synthesise randomised and non-
randomised studies by adjusting for bias in non-randomised studies
that is due to imbalances between treatment arms. Where informed
health care decision making requires the synthesis of evidence from
randomised and non-randomised study designs, such Bayesian
hierarchical models adjusting for covariate imbalances could
facilitate the optimal use of all available evidence.
Supporting Information
Figure S1 Flow chart depicting data simulation, analy-
sis and output for scenarios 1–6. The flow chart depicts the
simulation of the data in R, the analysis of the simulated data in
WinBUGS and the statistics used to assess the performance of the
four models.
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